A phase I multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV CTL multi-epitope peptide vaccine formulated with RC529-SE and GM-CSF given to HIV-1 positive adults on stable HAART.

Trial Profile

A phase I multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV CTL multi-epitope peptide vaccine formulated with RC529-SE and GM-CSF given to HIV-1 positive adults on stable HAART.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2006

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 08 Nov 2006 Status change
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top